The Danish government could face an annual expenditure of up to $4 billion if it decides to reimburse Novo Nordisk’s weight-loss drug, Wegovy, for nearly 900,000 individuals.
The Danish government could face an annual expenditure of up to $4 billion if it decides to reimburse Novo Nordisk’s weight-loss drug, Wegovy, for nearly 900,000 individuals.